Press release
Investigation announced for Investors in shares of Ovid Therapeutics Inc. (NASDAQ: OVID) over possible Violations of Securities Laws
An investigation for investors in Ovid Therapeutics Inc. (NASDAQ: OVID) shares over potential securities laws violations.
Investors who purchased shares of Ovid Therapeutics Inc. (NASDAQ: OVID), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ovid Therapeutics Inc. (NASDAQ: OVID) concerning whether a series of statements by Ovid Therapeutics Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New York based Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
On March 30, 2021, Ovid Therapeutics Inc. announced that Takeda Pharmaceutical Company Limited ("Takeda") had secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. Then, on June 17, 2024, Ovid issued a press release announcing that "Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency" and that "Takeda's Skyway study in Lennox-Gastaut syndrome missed its primary endpoint of reduction in major motor drop seizures[.]"
Shares of Ovid Therapeutics Inc. (NASDAQ: OVID) declined from $4.1 per share on February 12, 2024, to as low as $0.68 per share on June 26, 2024.
Those who purchased shares of Ovid Therapeutics Inc. (NASDAQ: OVID) have certain options and should contact the Shareholders Foundation.
ichael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Ovid Therapeutics Inc. (NASDAQ: OVID) over possible Violations of Securities Laws here
News-ID: 3620578 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of Organon & Co. (NYSE …
An investigation was announced for current long-term investors in shares of Organon & Co. (NYSE: OGN) concerning potential breaches of fiduciary duties by certain directors of Organon & Co.
Investors who are current long term investors in Organon & Co. (NYSE: OGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Lawsuit filed for Investors who lost money with shares of Charter Communications …
An investor, who purchased shares of Charter Communications, Inc. (NASDAQ: CHTR), filed a lawsuit over alleged violations of Federal Securities Laws by Charter Communications, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Charter Communications, Inc. (NASDAQ: CHTR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 14, 2025. NASDAQ: CHTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Investors in Vestis Corporation (NYSE: VSTS) over po …
An investigation was announced for current long-term investors in shares of Vestis Corporation (NYSE: VSTS) concerning potential breaches of fiduciary duties by certain directors of Vestis Corporation.
Investors who are current long term investors in Vestis Corporation (NYSE: VSTS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: VSTS…
iRobot Corporation (NASDAQ: IRBT) Investor Alert: Deadline in Lawsuit on Septemb …
A deadline is coming up on September 5, 2025 in the lawsuit filed for certain investors of iRobot Corporation (NASDAQ: IRBT) over alleged securities laws violations by iRobot Corporation.
Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and there are strict and short deadlines running. Deadline: September 5, 2025. iRobot Corporation (NASDAQ: IRBT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According…
More Releases for Ovid
Dup15q syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Ovid …
Dup15q syndrome therapies, such as Bexicaserin, UBE3A (ASO), and others, are expected to boost the Dup15q syndrome Market in the upcoming years.
DelveInsight has launched a new report on "Dup15q syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Dup15q syndrome, historical and forecasted epidemiology as well as the Dup15q syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom)…
Dravet Syndrome Treatment Market Future Business Opportunities 2025-2032 | Epyge …
New Report Highlights Key Insights in the Dravet Syndrome Treatment Market (2025-2032)
Coherent Market Insights has published a detailed report titled "Dravet Syndrome Treatment Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This study offers a deep dive into the Dravet Syndrome Treatment industry, covering market trends, growth drivers, challenges, competitive landscape, and regional insights. With 134 figures, tables, and charts, the report provides a data-rich analysis to help…
OVID Registered Announces Official National Launch on February 1, 2025
This professional-first brand is redefining the luxury hair tool industry with exclusivity, innovation, and empowerment.
LIVONIA, MI - December 23, 2024 - OVID Registered , the luxury hair tool company founded on a 'for us, by us' ethos, is proud to announce its official national launch on February 1, 2025. Designed exclusively for licensed salon owners and hairstylists, OVID Registered is reshaping the beauty industry by offering professional-grade tools, innovative programs,…
Dravet Syndrome Treatment Market Future Business Demand 2022-2028 | Epygenix The …
Coherent Market Insights has released a new research study on the "Dravet Syndrome Treatment Market" which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Dravet Syndrome Treatment Market Report detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The Dravet Syndrome Treatment Market research report…
Global Angelman Syndrome Market Scope Report Forecast to 2021-27 |key players ar …
Angelman syndrome (AS) is a complicated genetic condition affecting the neurological system primarily. Delay in development, intellectual incapacity, significant speech difficulty, and movement and balance issues are all symptoms of this illness (ataxia). The majority of the children who are affected also have recurring seizures (epilepsy) and a small head size.
This incorporates virtual consideration, at-home remedy conveyance, distant checking, advanced diagnostics and choice help, and self-administration applications for schooling, conduct…
OVID 19 PANDEMIC IMPACT ESTIMATES ON SLEEPING MASKS MARKET 2020- Dream Essential …
Sleeping Masks Market 2020 research report provides key statistics on the Market status of the Sleeping Masks manufacturers and is a importance source of guidance and direction for companies and individuals interested in the industry. The report primarily focuses on many critical points and trends of the industry which are useful for our esteemed clients. Further, in the Sleeping Masks market report, various definitions and categorization of the Sleeping Masks…
